Improving fluid management in sepsis treatment
Official title: Precision Guidance of Resuscitation and Deresuscitation in Sepsis
Funded at Daxor Corporation · NIH-10602712 · Data updated 2026-11-12
This study is looking at how to improve fluid treatment for people with sepsis by using a special device to measure blood volume, so that each patient gets just the right amount of fluids they need, which could help them recover better.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Daxor Corporation NIH-funded |
| Lab location | 1 site (Oak Ridge, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $305,000 |
| NIH project number | 1R43GM149094-01 |
| Project ID | NIH-10602712 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are experiencing sepsis or septic shock.
✕Less likely to help
Patients who are not critically ill or do not have sepsis may not benefit from this research.
What this research studies
This research investigates how to better manage fluid resuscitation in patients with sepsis, a serious condition that affects millions. It challenges the traditional approach of administering large amounts of fluids based on general guidelines, instead focusing on precise measurements of blood volume using advanced technology. By utilizing Daxor’s BVA-100 device, the study aims to tailor fluid treatment to individual patients' needs, potentially leading to better outcomes. The research will involve a randomized controlled trial to assess the effectiveness of this personalized approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer fluid management strategies for patients with sepsis.
How similar studies have gone: Previous studies have shown promising results with personalized fluid management approaches in critically ill patients, indicating potential for success in this research.
Where this research is happening
-
Daxor Corporation
Oak Ridge, United States Active
Researchers
- Principal investigator: Feldschuh, Jonathan — Daxor Corporation
- Study coordinator: Feldschuh, Jonathan
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.